New data from the DanGer Shock trial, published in the New England Journal of Medicine, shows Johnson & Johnson's Impella CP heart pump significantly improves long-term survival rates in patients experiencing cardiogenic shock following a heart attack. The 10-year data reveals a substantial reduction in mortality.

New data on Cytokinetics' aficamten, presented at the European Society of Cardiology Congress 2025, demonstrates its superiority over metoprolol in treating hypertrophic cardiomyopathy (HCM). Findings show improved cardiac structure and function, with a low incidence of atrial fibrillation. The FDA is reviewing aficamten's application.

Texas Monthly Presents, a docuseries showcasing Texas Monthly's storytelling, returns to Texas PBS stations with 13 new episodes. The series explores diverse Texas themes, building on the success of its initial four-episode run. Viewers can watch on Sundays at 6 p.m. CT or stream online.

New data from the HELIOS-B Phase 3 trial show Alnylam's AMVUTTRA (vutrisiran) provides sustained cardiovascular benefits in patients with ATTR-CM for up to 48 months. This includes a significant reduction in mortality and cardiovascular events. The findings reinforce vutrisiran's potential as a first-line treatment.